IP Library Granted Patent US 8,816,046
Granted Patent B2
US 8,816,046 · App. 12/679,459 · Granted Aug 26, 2014

Compositions and methods for CaMKII inhibitors and uses thereof

Inventor: K. Ulrich Bayer (Denver, CO)
Assignee: The University of Colorado, a body corporate
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,816,046
App. No.
12/679,459
Granted
Aug 26, 2014
Kind
B2
Abstract

Embodiments herein generally relate to methods, compositions and uses of CaMKII inhibitors. Other embodiments relate to methods, compositions and uses of agents that target CaMKII. Yet further embodiments relate to compositions, methods and uses of CaMKIIN-derived molecules and other CaMKII inhibitor molecules that inhibit autonomous CaMKII activity. In accordance with these embodiments, compositions that inhibit autonomous CaMKII activity may be used for treating conditions causing neuronal cell death, for treating cancer or for treating neurodegenerative disorders.

Claims (11)

1. A composition comprising a peptide consisting of 19, 20 or 21 consecutive amino acids of the sequence of SEQ ID NO:1 or a pharmaceutically acceptable derivative or salt thereof.

2. The composition of claim 1 , further comprising a cell-transfer/penetrating agent associated with the peptide.

3. The composition of claim 2 , wherein the cell-transfer/penetrating agent is fused to the peptide.

4. The composition of claim 2 , wherein the cell-transfer/penetrating agent comprises tat, ant, meristyl-group, palmityl-group or combination thereof.

5. The composition of claim 1 , wherein the peptide is 19 consecutive amino acids of SEQ ID NO:1.

6. The composition of claim 2 , further comprising one or more agents for treating a neurodegenerative condition.

7. A composition comprising a peptide consisting of 19, 20 or 21 consecutive amino acids of the sequence Lys Arg Xaa1 Pro Lys Leu Gly Gln Ile Gly Arg Xaa2 Xaa3 Arg Val Val Ile Glu Asp Asp Arg (SEQ ID NO. 23), wherein position 3, Xaa1, is selected from the group consisting of proline, alanine, arginine or lysine; position 12, Xaa2, is selected from the group consisting of serine, valine or arginine; and position 13, Xaa3, is selected from the group consisting of lysine or alanine, or a pharmaceutically acceptable derivative or salt thereof.

8. A kit comprising:

a vessel; and

one or more compositions comprising one or more of the compositions of claim 1 or claim 7 .

9. The kit of claim 8 , further comprising a delivery device for administering the one or more compositions.

Assignments (2)
CONFIRMATORY LICENSE Recorded Jul 30, 2018
From: UNIVERSITY OF COLORADO
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 047258/0217 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 30, 2010
From: BAYER, K. ULRICH
To: THE REGENTS OF THE UNIVERSITY OF COLORADO
Reel/Frame 025073/0735 →
Continuity (3)
Provisional Application 60975329 · Sep 26, 2007
Provisional Application 60980766 · Oct 17, 2007
Related Publication 20100285033A1 · Nov 11, 2010